Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Anyone think it was odd

<< Previous

Bullboard Posts

Next >>

Comment by MHemorrhageon Feb 14, 2021 8:53pm

90 Views

Post# 32566367

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Anyone think it was odd

That's a good idea, I could post a visual comparing the market caps rather than spelling it out. You can't post visuals/graphics in Reddit's text threads, but I'll create a visual comparison and upload it to Imgur (Reddit's image hosting service) and link it to my thread. And yes I hadn't thought about comparing to other oncology companies' market caps, too - do we know of any comparable (Phase I or lesser)? Or separate value breakdowns on existing established companies' Phase I programs?

longterm56 wrote: You should also include a simplified table of the comparable companies (in both oncology and NASH) and their market caps (tables were posted here a few weeks back). Make it so simple and concise so that one can understand it quickly and take away the main thought: THTX should already be 3-4 times it's price for either NASH or oncology, but it has BOTH + real revenues!

-LT